Safety and Efficacy of Pro-ocularâ„¢ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease
Phase 2
Active, not recruiting
- Conditions
- Ocular Graft-versus-host Disease
- Interventions
- Drug: PlaceboDrug: Pro-ocularâ„¢ Topical Gel 1%
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Glia, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT04769648
- Locations
- 🇺🇸
BostonSight, Needham, Massachusetts, United States
Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
Phase 2
Completed
- Conditions
- Contact Lens DiscomfortContact Lens-induced Corneal DisorderContact Lens Acute Red EyeContact Lens-induced Corneal Fluorescein Staining
- Interventions
- Drug: CLM2 topical gelDrug: Placebo topical gel
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Glia, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03994406
- Locations
- 🇺🇸
UC Berkeley Clinical Research Center, Berkeley, California, United States
Treatment Safety and Efficacy of Pro-ocularâ„¢ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
Phase 2
Completed
- Conditions
- Chronic Ocular Graft-versus-host Disease
- Interventions
- Drug: Pro-ocularâ„¢ topical gelDrug: Placebo topical gel
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Glia, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT03990051
- Locations
- 🇺🇸
Massachusetts Eye and Ear Longwood, Boston, Massachusetts, United States
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Glia, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT02656394
- Locations
- 🇺🇸
New York Eye & Ear Infirmary of Mount Sinai, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath